A Study of MP-101 in Dementia-Related Psychosis and/or Ag... | NCT03044249

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
MP-101	Experimental	Week 0: Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).	Drug: MP-101
Placebo	Placebo Comparator	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.	Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
MP-101	Drug	Capsules	MP-101	LY2979165 LY2812223

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Percentage of Participants With 30% Improvement From Baseline in the Neuropsychiatric Inventory (NPI) - Psychosis Subscale or Aggression/Agitation Subscale Score	The NPI is a questionnaire that quantifies behavioral changes in dementia. For each of 12 domains there are 4 scores: Frequency (scale:1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale: 0=not at all distressing to 5=extremely distressing). An NPI response was defined as at least a 30% improvement from baseline on the NPI Psychosis sub-score (for participants with a psychosis diagnosis (Delusions and Hallucinations)) or the NPI Aggression/Agitation sub-score (for participants with an agitation/aggression diagnosis). The delusions, hallucinations, and aggression/agitation domain scores were added together to form a core total score with score range of 0 to 36. Lower score=less severity. A negative change score from baseline indicates improvement.	Week 10

Secondary Outcomes

Measure	Description	Time Frame
Percentage of Participants With Improvement From Baseline in the Clinical Global Impression of Improvement (CGI-I) at Week 10	The CGI rating scale, which measures symptom severity, treatment response and the efficacy of treatments, is used in clinical studies on mental disorders. CGI Improvement scale is a 7 point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Females must be of non-childbearing potential, defined as women greater than or equal to (≥) 60 years of age, postmenopausal women ≥50 and less than (<) 60 years of age who have had a cessation of menses for at least 12 months, or women who are congenitally or surgically sterile
Males must agree to use 2 forms of highly effective birth control with female partners of childbearing potential while enrolled in the study, and for at least 28 days following the last dose
Ambulatory (with or without walking device) with a stable gait
Have a Mini-Mental State Examination (MMSE) score of 10 to 24
Meet clinical criteria for one of the following disorders: dementia associated with Parkinson's disease, dementia with Lewy bodies, possible or probable Alzheimer's disease, frontotemporal degeneration spectrum disorders, vascular dementia
Able to communicate verbally
Have an NPI score of ≥4 on either individual item (delusions or hallucinations) or ≥6 on the Psychosis Subscale (combined delusions and hallucinations), or an NPI score of ≥4 on agitation/aggression domain
Have a reliable caregiver who provides written informed consent to participate and who is in frequent contact with the patient (defined as spending at least 4 hours/day at least 4 days/week with the patient and who is knowledgeable about the patient's daytime and nighttime behaviors). The caregiver must be able to communicate with site personnel, and opinion of the investigator, must understand the written protocol-specified questionnaires. If a caregiver cannot continue, one replacement caregiver will be allowed if the above criterion is met
Must be on a stable dose of cholinesterase inhibitor and/or memantine, if applicable
If taking antipsychotic drugs or any drug intended to treat psychosis, must be on a stable treatment regimen for ≥1 month prior to the study
Have venous access sufficient to allow for blood sampling per the protocol
Have clinical laboratory test results within normal reference range for the population or investigative site
Are capable of participating in all study assessments
Are able and willing to provide consent (patients and caregivers)

Exclusion Criteria:

Have a history of significant psychotic disorders (including, schizophrenia, delusional disorder, substance abuse psychosis that lasted over 6 months, major depressive disorder or bipolar disorder with psychotic episodes)
Has a history of ischemic stroke within the last 12 months or any evidence of hemorrhagic stroke
Have renal impairment as defined by Estimated Glomerular Filtration Rate (eGFR) <45 milliliters per minute per 1.73 square meters (ml/min/1.73m2)
Have significant cardiovascular, respiratory, gastrointestinal, renal, hematologic, or oncologic comorbidities that could impact patient safety and study participation over 10 weeks
Have a history of seizures or other condition that would place the patient at increased risk of seizures.
Are, in the investigator's judgment, at risk for suicide, or as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS)
Have a Fridericia's corrected QT interval (QTcF) greater than (>) 450 milliseconds (ms) for males or 470 ms for females
Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, at least 3 months (or more) must have passed
In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Name	Affiliation	Role
Mediti Pharma	Mediti Pharma Inc.	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Dignity Health (St. Joseph Hospital and Medical Center)		Phoenix	Arizona	85013	United States
Neuro-Therapeutics Inc

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
FG001	MP-101	Week 0: Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Feb 13, 2018	Jan 28, 2021

Arm/Group Information

ID	Title	Description
BG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
BG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).
BG002	Total	Total of all reporting groups

Units	Counts
Participants	BG00042 BG00139 BG00281

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00075.3± 9.44 BG00174.0± 7.66 BG00274.7± 8.60

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG00028 BG00127 BG002

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG00010 BG0016 BG002

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0001 BG0010 BG002

Region of Enrollment

Count of Participants

Participants

Title

Denominators

Categories

Canada

Title	Measurements
	BG0002 BG0013 BG002

Neuropsychiatric Inventory (NPI) Psychosis Score

The NPI Psychosis subscale score was the sum of the delusions and hallucinations items of the standard 12-item NPI that measured psychosis symptoms in participants with dementia. Scores for each subscale (frequency x severity) were calculated for each item score and ranged from 0 to 24 with higher scores indicating more frequent and/or severe neuropsychiatric symptoms.

Mean

Standard Deviation

units on a scale

Title

Denominators

Categories

Title	Measurements
	BG0008.4± 6.36 BG001

NPI Agitation/Aggression Score

The NPI Psychosis subscale score for Agitation/Aggression consists of Agitation/Aggression item of the standard 12-item NPI that measured psychosis symptoms in participants with dementia. Scores for each subscale (frequency x severity) were calculated for each item score and ranged from 0 to 12 with higher scores indicating more frequent and/or severe neuropsychiatric symptoms.

Mean

Standard Deviation

units on a scale

Title

Denominators

Categories

Title	Measurements
	BG0005.8± 3.34 BG001

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Percentage of Participants With 30% Improvement From Baseline in the Neuropsychiatric Inventory (NPI) - Psychosis Subscale or Aggression/Agitation Subscale Score

The NPI is a questionnaire that quantifies behavioral changes in dementia. For each of 12 domains there are 4 scores: Frequency (scale:1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale: 0=not at all distressing to 5=extremely distressing). An NPI response was defined as at least a 30% improvement from baseline on the NPI Psychosis sub-score (for participants with a psychosis diagnosis (Delusions and Hallucinations)) or the NPI Aggression/Agitation sub-score (for participants with an agitation/aggression diagnosis). The delusions, hallucinations, and aggression/agitation domain scores were added together to form a core total score with score range of 0 to 36. Lower score=less severity. A negative change score from baseline indicates improvement.

All randomized participants who received at least one dose of study drug who completed at least Week 4 with NPI scores but were not withdrawn due to early termination of the study.

Posted

Number

percentage of participants

Week 10

ID	Title	Description
OG000	Placebo	Participants received 3 capsules of placebo orally once daily (QD) during Week 0, Week 1 and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD ((1 x 20-mg caps and 2 placebo caps)). Week 1: Participants received 40 mg MP-101 orally QD ((2 x 20-mg caps and 1 placebo caps)). Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Units	Counts
Participants	OG00033 OG00126

Title

Denominators

Categories

Title	Measurements
	OG00058 OG00162

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Fisher Exact		0.48		Response Ratio	4			2-Sided	90	-18	25					Superiority

Secondary

Percentage of Participants With Improvement From Baseline in the Clinical Global Impression of Improvement (CGI-I) at Week 10

The CGI rating scale, which measures symptom severity, treatment response and the efficacy of treatments, is used in clinical studies on mental disorders. CGI Improvement scale is a 7 point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline CGI-I measurement.

Posted

Number

percentage of participants

Week 10

ID	Title	Description
OG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Secondary

Change From Baseline in NPI Total Score

All randomized participants who received at least one dose of study drug who completed at least Week 4 with NPI scores.

Posted

Mean

Standard Error

score on a scale

Baseline, Week 10

ID	Title	Description
OG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Secondary

Change From Baseline in NPI Core Total Score

The NPI is a questionnaire that quantifies behavioral changes in dementia. For each of 12 behavioral domains there are 4 scores: Frequency (scale: 1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale: 0=not at all distressing to 5=extremely distressing). The NPI CoreTotal Score is calculated by adding the Individual Item Scores for all 3 domains (hallucinations, delusions, and agitation/aggression) to yield a possible NPI Core Total Score of 0 to 36. Lower score=less severity. A negative change score from baseline indicates improvement.

All randomized participants who received at least one dose of study drug who completed at least Week 4 with NPI scores.

Posted

Mean

Standard Error

score on a scale

Baseline, Week 10

ID	Title	Description
OG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Secondary

Number of Participants With NPI Caregiver Distress

The NPI is a questionnaire that quantifies behavioral changes in dementia. For each of 12 domains there are 4 scores: Frequency (scale:1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale:0=not at all distressing to 5=extremely distressing). The NPI Psychosis Subscale Caregiver Distress Score is calculated by adding Individual Item Scores for the domains of Delusions and Hallucinations, to yield a possible total score of 0 to 10. Lower score=less severity. A negative change score from baseline=improvement.

All randomized participants who received at least one dose of study drug who completed at least Week 4 with NPI scores.

Posted

Count of Participants

Participants

Week 10

ID	Title	Description
OG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Secondary

Change From Baseline in NPI Domains - Anxiety

The 12 individual items in NPI that quantify changes in dementia are delusions, hallucinations, agitation, depression, anxiety, apathy, disinhibition, irritability, euphoria, aberrant motor behavior, nighttime behaviors, and appetite. For each of 12 behavioral domains there are 4 scores: Frequency (scale:1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale: 0=not at all distressing to 5=extremely distressing). The NPI Psychosis Subscale Anxiety consists of anxiety item to yield a possible NPI Score of 0 to 12. Lower score=less severity. A negative change score from baseline indicates improvement.

All randomized participants who received at least one dose of study drug who completed at least Week 4 with NPI scores.

Posted

Mean

Standard Deviation

units on a scale

Baseline, 10 Weeks

ID	Title	Description
OG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Secondary

Number of Participants With Any Treatment Emergent Adverse Event

Number of participants with untoward medical occurrences that emerge during the treatment period, having been absent pretreatment, or worsen relative to the pretreatment state, which do not necessarily have a causal relationship with this treatment. A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs) is located in the reported adverse events module.

All randomized participants who received at least one dose of study drug.

Posted

Count of Participants

Participants

Baseline Up to 10 Weeks

ID	Title	Description
OG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Units	Counts
Participants

Secondary

Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III

Part III of the UPDRS is an investigator-scored scale used to assess the motor symptoms of patients with Parkinson's disease. The investigator rates the patient on 14 items based on observation or the performance of a task the patient performs (even in the context of any comorbidities) on a 5-point scale. The scores range from 0 to 4, with higher scores indicating greater impairment. The total UPDRS score was calculated as the sum of all items, ranging from 0 to 56 with higher scores indicating greater impairment. If any individual item was missing, the UPDRS score was be set to missing.

All randomized participants who received at least one dose of study drug who completed at least Week 4 with NPI scores.

Posted

Mean

Standard Error

units on a scale

Baseline, Week 10

ID	Title	Description
OG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
OG001	MP-101	Week 0: Participants received 20 mg MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).

Secondary

Population Pharmacokinetics (PK): Plasma Levels of MP-101 and Metabolite

Summary statistics of sparse blood concentration samples at weeks 2, 4, 6, 10 and Early Termination obtained utilizing a population PK approach.

All participants who received at least one dose of MP-101 and had evaluable PK data.

Posted

Geometric Mean

Geometric Coefficient of Variation

Nanomoles per liter (nmol/L)

Week 2: 4-8 hours post-dose; Week 4: Predose, 0-2 hours postdose; Week 6: 8-12 hours postdose; Week 10: 2- 4 hours;Early Termination

ID	Title	Description
OG000	MP-101	Participants received 60 mg MP-101 orally QD (3 x 20-mg caps).
OG001	LY2812223 (MP-101 Metabolite)	Participants received 60 mg MP-101 orally QD (3 x 20-mg caps).

Units	Counts
Participants	OG000

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Placebo	Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.	0	42	4	42	12	42
EG001	MP-101	Week 0: Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps. Week 1: Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps. Week 2 through Week 9: Participants received 60 mg MP-101 orally QD (3 x 20-mg caps ).	1	39	4	39	22	39

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Pneumonia	Infections and infestations	MedDRA 22.1	Systematic Assessment	EG0002 events2 affected42 at risk EG0010 events0 affected39 at risk
Sepsis	Infections and infestations	MedDRA 22.1	Systematic Assessment	EG0001 events1 affected42 at risk EG0010 events0 affected39 at risk
Fall	Injury, poisoning and procedural complications	MedDRA 22.1	Systematic Assessment	EG0000 events0 affected42 at risk EG0011 events1 affected39 at risk
Hip fracture	Injury, poisoning and procedural complications	MedDRA 22.1	Systematic Assessment	EG0000 events0 affected42 at risk EG0011 events1 affected39 at risk
Dementia	Nervous system disorders	MedDRA 22.1	Systematic Assessment	EG0000 events0 affected42 at risk EG0011 events1 affected39 at risk
Unresponsive to stimuli	Nervous system disorders	MedDRA 22.1	Systematic Assessment	EG0000 events0 affected42 at risk EG0011 events1 affected39 at risk
Abnormal behaviour	Psychiatric disorders	MedDRA 22.1	Systematic Assessment	EG0000 events0 affected42 at risk EG0011 events1 affected39 at risk
Mental status changes	Psychiatric disorders	MedDRA 22.1	Systematic Assessment	EG0000 events0 affected42 at risk EG0011 events1 affected39 at risk
Psychotic disorder	Psychiatric disorders	MedDRA 22.1	Systematic Assessment	EG0001 events1 affected42 at risk EG0010 events0 affected39 at risk
Suicidal ideation	Psychiatric disorders	MedDRA 22.1	Systematic Assessment	EG0001 events1 affected42 at risk EG0010 events0 affected39 at risk
Acute kidney injury	Renal and urinary disorders	MedDRA 22.1	Systematic Assessment	EG0001 events1 affected42 at risk EG0010 events0 affected39 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Nausea	Gastrointestinal disorders	MedDRA 22.1	Systematic Assessment	EG0002 events2 affected42 at risk EG0014 events4 affected39 at risk
Vomiting	Gastrointestinal disorders	MedDRA 22.1	Systematic Assessment	EG0001 events1 affected42 at risk EG0014 events4 affected39 at risk
Fatigue	General disorders	MedDRA 22.1	Systematic Assessment	EG0002 events2 affected42 at risk EG0013 events3 affected39 at risk
Contusion	Injury, poisoning and procedural complications	MedDRA 22.1	Systematic Assessment	EG0001 events1 affected42 at risk EG0012 events2 affected39 at risk
Fall	Injury, poisoning and procedural complications	MedDRA 22.1	Systematic Assessment	EG0003 events3 affected42 at risk EG0014 events3 affected39 at risk
Dizziness	Nervous system disorders	MedDRA 22.1	Systematic Assessment	EG0001 events1 affected42 at risk EG0014 events4 affected39 at risk
Headache	Nervous system disorders	MedDRA 22.1	Systematic Assessment	EG0000 events0 affected42 at risk EG0012 events2 affected39 at risk
Confusional state	Psychiatric disorders	MedDRA 22.1	Systematic Assessment	EG0002 events2 affected42 at risk EG0015 events5 affected39 at risk

ID	Term
D011618	Psychotic Disorders
D003704	Dementia
D000374	Aggression
D011595	Psychomotor Agitation
D000544	Alzheimer Disease

ID	Term
D019967	Schizophrenia Spectrum and Other Psychotic Disorders
D001523	Mental Disorders
D001927	Brain Diseases
D002493	Central Nervous System Diseases
D009422	Nervous System Diseases
D019965	Neurocognitive Disorders
D000096762	Aberrant Motor Behavior in Dementia
D001526	Behavioral Symptoms
D001519	Behavior
D012919	Social Behavior
D020820	Dyskinesias
D009461	Neurologic Manifestations
D011596	Psychomotor Disorders
D019954	Neurobehavioral Manifestations
D012816	Signs and Symptoms
D013568	Pathological Conditions, Signs and Symptoms
D024801	Tauopathies
D019636	Neurodegenerative Diseases